A review of recent findings from several FDA Postmarketing Adverse Drug Experience inspections will be discussed using Warning Letters to identify observations.

Have an account?

Pragmatic Approaches to Drug Safety Across the Premarketing and Postmarketing Continuum

Session 26: FDA Warning Letters

Session Chair(s)

Jill W. Buckley, PharmD

Be informed and stay engaged.